Kewaunee Scientific Corporation — Fiscal 2023 Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2023, compared with fiscal year ended April 30, 2022. The filing is an annual report, not a quarterly filing; the provided “2022 Q4” metadata does not match the filing period.
Business Context
Kewaunee designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure, including casework, fume hoods, modular systems, workstations, biological safety cabinets, and epoxy-resin surfaces. Customers include pharmaceutical, biotechnology, industrial, educational, healthcare, governmental, and manufacturing organizations.
The Company operates Domestic and International segments, with manufacturing in Statesville, North Carolina and Bangalore, India. International sales represented approximately 33% of fiscal 2023 revenue, and 34% of revenue was derived from sales outside the United States. Three domestic dealers accounted for approximately 36% of total sales.
Key Financial Metrics
| Metric | Fiscal 2023 | Fiscal 2022 | Change |
|---|---|---|---|
| Net sales | $219.5 million | $168.9 million | +30.0% |
| Gross profit | $35.6 million | $24.2 million | +46.9% |
| Gross margin | 16.2% | 14.3% | +190 basis points |
| Operating earnings (loss) | $5.4 million | $(2.6) million | Improved |
| Earnings (loss) before taxes | $4.5 million | $(2.5) million | Improved |
| Net earnings (loss) attributable to Kewaunee | $0.7 million | $(6.1) million | Improved |
| Diluted earnings (loss) per share | $0.25 | $(2.20) | Improved |
| Operating expenses | $30.2 million | $26.8 million | +12.7% |
| Interest expense | $1.7 million | $0.6 million | Higher |
| Income tax expense | $3.1 million | $3.5 million | Lower |
Segment Performance
- Domestic sales: $146.7 million, up 15.7%, primarily due to pricing on new orders reflecting higher raw-material costs.
- International sales: $72.8 million, up 73.2%, driven by delivery of several large projects in India, Asia, and Africa.
- International profitability: International earnings before taxes were $7.4 million versus $3.6 million; Domestic earnings before taxes were $3.4 million versus a $0.2 million loss.
Cash Flow, Liquidity, Debt, and Capital Resources
- Operating activities used $3.8 million of cash, an improvement from $7.9 million used in fiscal 2022, but operations remained cash-flow negative.
- Investing activities used $4.1 million, primarily for capital expenditures of $4.1 million, compared with $1.9 million of capital expenditures in fiscal 2022.
- Financing activities provided $14.9 million, including $13.6 million of final proceeds from the prior-year sale-leaseback transaction and $2.0 million of net short-term borrowings.
- Cash, cash equivalents, and restricted cash totaled $13.8 million at year-end, including $8.1 million of unrestricted cash and $5.7 million of restricted cash supporting customer performance guarantees.
- The Company had $3.5 million outstanding under its $15.0 million secured revolving credit facility, with $10.3 million of remaining borrowing capacity. The facility matures December 19, 2025 and carried a 9.02% borrowing rate at April 30, 2023.
- The Company remained in compliance with its revolving-credit financial covenants.
- Working capital was $47.9 million, compared with $49.3 million in the prior year; the current ratio was 2.2-to-1.0.
- Capital expenditures are expected to be approximately $4.4 million in fiscal 2024, funded primarily by operating cash flow and, if needed, revolving borrowings.
- The Company declared and paid no common-stock dividends in either fiscal 2023 or fiscal 2022.
Material Changes Versus the Prior Period
- Revenue increased substantially, led by large international project deliveries and domestic price increases.
- Gross margin expanded because International sales carry higher margins and domestic pricing improved.
- The Company returned to profitability after a significant fiscal 2022 loss.
- Interest expense increased due primarily to the sale-leaseback financing arrangement, partially offset by lower revolving-credit interest.
- Pension results shifted from $355,000 of income to $71,000 of expense, primarily due to a lower expected return on plan assets.
- Backlog declined to $147.9 million from $173.9 million, mainly because of substantial completion of the Dangote Oil project in Nigeria and lower new orders in the ASEAN marketplace. Management stated that U.S. and Indian backlog remained similar to prior-year levels.
- The China subsidiary closure initiated in 2019 was completed in March 2023. Fiscal 2023 restructuring expense was $32,000, partly offset by $51,000 of bad-debt recoveries.
- The Company continued to account for the Statesville property sale-leaseback as a financing transaction rather than a sale. The related financing liability was $28.8 million at April 30, 2023, with total future minimum payments of $43.9 million.
- The effective tax rate was adversely affected by valuation-allowance changes and the requirement under amended Internal Revenue Code Section 174 to capitalize and amortize research and experimentation expenditures over five years.
Outlook, Commentary, and Risks
Management described fiscal 2023 as a transition year following a disruptive period involving the global pandemic, inflation, labor shortages, and supply-chain disruptions. Management believes the Company is positioned for fiscal 2024 based on its global management team, backlog, improved manufacturing capabilities, and continued investment in laboratory and healthcare construction projects.
Management cautioned that demand is difficult to forecast because the Company frequently acts as a subcontractor or dealer supplier and depends on the timing and progress of construction projects. At April 30, 2023, the Company estimated that at least 91% of backlog would ship during fiscal 2024, subject to customer rescheduling and construction delays.
- Fixed-price contracts expose margins to increases in steel, stainless steel, wood, resin, labor, energy, freight, tariffs, and other input costs.
- Customer construction delays, design changes, shipping interruptions, and supply constraints can delay production, shipments, and revenue recognition.
- Dependence on major dealers and a national distributor creates customer-concentration risk.
- International operations expose the Company to foreign-exchange, geopolitical, regulatory, tariff, political, and economic risks. Approximately 27% of fiscal 2023 sales were denominated in currencies other than the U.S. dollar.
- The Company had $5.6 million of foreign bank guarantees outstanding, primarily expiring in fiscal 2024, collateralized by certain Indian subsidiary assets.
- Cash held at financial institutions may exceed FDIC insurance limits, creating potential liquidity exposure in the event of bank failure.
- Cybersecurity incidents, information-technology failures, pandemics, natural disasters, and geopolitical conflict could disrupt operations and supply chains.
- The Company was involved in ordinary-course claims and litigation, but management did not expect presently pending matters to have a material adverse effect.
Management stated that disclosure controls and internal control over financial reporting were effective as of April 30, 2023. The independent auditor issued an unqualified opinion and reported no critical audit matters; the auditor was not required to provide an internal-control attestation because of the Company’s smaller-reporting-company status.
Investor Verification Checklist
- Verify whether operating cash flow turns positive in fiscal 2024 and whether cash generation supports planned capital expenditures.
- Monitor backlog conversion, new order rates, and customer concentration, particularly following completion of the Dangote Oil project.
- Assess whether pricing actions continue to offset raw-material, labor, freight, tariff, and other cost inflation.
- Review liquidity and covenant compliance under the secured revolving facility, including the effect of the 9.02% borrowing rate.
- Evaluate the long-term obligations and renewal economics associated with the $28.8 million sale-leaseback financing liability and 20-year property lease.
- Track the valuation allowance on deferred tax assets, the effects of Section 174 research-cost amortization, and the unusually high 69.8% effective tax rate.
- Assess international execution, foreign-exchange exposure, performance guarantees, and geopolitical or supply-chain risks.
- Confirm that no material litigation, cybersecurity incident, customer loss, or control deficiency has arisen after the April 30, 2023 reporting date.